Abbott showcases expanding evidence across its cancer diagnostics portfolio at ASCO 2026

Rhea-AI Summary

Abbott (NYSE:ABT) will showcase 11 cancer diagnostics abstracts at the ASCO 2026 Annual Meeting in Chicago, May 29–June 2, 2026. Presentations span multi-cancer early detection, molecular residual disease, breast recurrence risk, colorectal screening and pipeline innovation.

Highlights include new MRD data from the PARTNER trial in early triple-negative breast cancer, early real-world data on the Cancerguard multi-cancer early detection blood test, AI-driven risk stratification using the Oncotype DX Breast Recurrence Score, a vaginal-swab-based endometrial cancer test, and updated analyses for the Cologuard colorectal cancer screening test.

AI-generated analysis. How Rhea-AI works. Not financial advice.

News Market Reaction – ABT

-0.85%

-0.85% News Effect

On the day this news was published, ABT declined 0.85%, reflecting a mild negative market reaction.

Data tracked by StockTitan Argus on the day of publication.

Market Context

This announcement highlights Abbott’s broad oncology diagnostics push, with 11 abstracts at ASCO 202...

Analysis

This announcement highlights Abbott’s broad oncology diagnostics push, with 11 abstracts at ASCO 2026 covering MCED, MRD, breast recurrence scoring, and pipeline programs like an endometrial cancer test. It builds on recent data from AACR 2026 and integration of Precision Oncology into OncoEMR. Investors may track how consistently these tools demonstrate improved detection, low patient burden, and clearer treatment decisions, along with future disclosures on adoption trends and revenue contribution.

Key Figures

ASCO 2026 abstracts: 11 abstracts ASCO 2026 dates: May 29 – June 2, 2026 MCED session time: June 1, 2026, 1:30–4:30 p.m. CT +4 more

7 metrics

ASCO 2026 abstracts 11 abstracts Cancer diagnostics data across portfolio at ASCO 2026

ASCO 2026 dates May 29 – June 2, 2026 American Society of Clinical Oncology Annual Meeting timeline

MCED session time June 1, 2026, 1:30–4:30 p.m. CT Cancerguard Multi-Cancer Early Detection presentations

MRD session time June 1, 2026, 1:30–4:30 p.m. CT Oncodetect Molecular Residual Disease test presentations

Breast score session June 1, 2026, 10:51 a.m. Oncotype DX Breast Recurrence Score presentation slot

Pipeline session time June 1, 2026, 9:00 a.m.–12:00 p.m. CT Endometrial cancer test from vaginal swab

Cologuard session Online only Cologuard test adenoma detection meta-analysis

Historical Context

5 past events · Latest: Apr 28 (Positive)

Pattern 5 events

Date	Event	Sentiment	24h Move	Catalyst
Apr 28	Imaging platform clearance	Positive	+1.1%	FDA clearance and CE Mark for Ultreon 3.0 AI coronary imaging platform.
Apr 17	Clinical data update	Positive	+1.4%	AACR 2026 Cancerguard MCED data highlighting multi-biomarker detection performance.
Apr 16	Earnings and acquisition	Neutral	-6.0%	Q1 2026 results and updated guidance incorporating Exact Sciences acquisition.
Apr 09	Survey findings	Neutral	-0.8%	U.S. survey on chronic disease perceptions and new educational partnership.
Mar 30	Oncology access expansion	Positive	-2.0%	Integration of Precision Oncology portfolio into Flatiron OncoEMR platform.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Pattern Detected

Recent clinical and technology milestones often saw modest positive reactions, while some strategic and access-expansion news drew muted or negative moves.

Recent Company History

In the past two months, Abbott reported multiple oncology and cardiovascular milestones. On Mar 30, it expanded Precision Oncology access via Flatiron’s OncoEMR, but shares fell 2.03%. An April survey-focused release on Apr 9 had a small negative move. Clinical and technology wins on Apr 16 and Apr 28 (AACR Cancerguard data and Ultreon 3.0 FDA clearance/CE Mark) saw gains of 1.4% and 1.14%. First-quarter 2026 results and Exact Sciences guidance on Apr 16 triggered a larger -6% decline. Today’s ASCO 2026 diagnostics data fits the ongoing theme of oncology diagnostics expansion.

Key Terms

molecular residual disease, multi-cancer early detection, circulating tumor dna, whole-exome sequencing, +4 more

8 terms

molecular residual disease medical

"The Oncodetect® Molecular Residual Disease (MRD) Test"

Molecular residual disease is the tiny amount of cancer that can remain in the body after treatment and is detectable only by sensitive tests that find cancer DNA or other molecular traces. It matters to investors because these measurements can predict relapse, guide whether additional therapy is needed, and shape the market for diagnostics and drugs—much like finding embers after a fire helps decide if more firefighting is required.

multi-cancer early detection medical

"The Cancerguard® Multi-Cancer Early Detection (MCED) Test"

A multi-cancer early detection test is a medical screening tool—often a simple blood test—that looks for biological signals, such as abnormal DNA or protein patterns, that could indicate many different cancers before symptoms appear. For investors it matters because successful tests can reshape demand for diagnostics, influence healthcare spending and insurance coverage, and create new revenue streams or risks for companies across diagnostics, treatment and screening services; think of it as a smoke alarm that can warn of problems throughout an entire house rather than just one room.

circulating tumor dna medical

"tumor-informed circulating tumor DNA MRD assays in patients with early"

Fragments of DNA shed by cancer cells into the bloodstream that act like tiny fingerprints of a tumor; they can be detected with a blood test rather than a biopsy. Investors care because circulating tumor DNA (ctDNA) enables faster, lower-cost ways to detect disease, track treatment response, identify emerging resistance and enroll patients in trials—factors that can materially affect the commercial prospects of diagnostics and therapeutics.

whole-exome sequencing medical

"Evaluation of whole-exome & whole-genome sequencing tumor-informed"

Whole-exome sequencing is a laboratory method that reads the portions of an individual’s DNA that directly code for proteins (the exome), which is a small but information-rich slice of the genome. For investors it matters because it’s a faster, cheaper way to find genetic changes linked to disease, guiding diagnostic tests, drug targets and personalized treatments—similar to scanning the most relevant pages of a large manual to find where errors occur.

whole-genome sequencing medical

"Evaluation of whole-exome & whole-genome sequencing tumor-informed"

Whole-genome sequencing is the process of reading an organism’s entire DNA instruction manual to capture all genetic information rather than just selected parts. For investors, it matters because having the full genetic picture can reveal new diagnostics, drug targets, or personalized treatments that drive product value, regulatory approvals, and long-term revenue potential, while improvements in speed and cost can expand market reach like making a complex map easier and cheaper to produce.

neoadjuvant chemotherapy medical

"breast cancer (TNBC) receiving neoadjuvant chemotherapy (NAC) with or without"

Neoadjuvant chemotherapy is drug treatment given before the main medical procedure—typically surgery—to shrink a tumor or reduce disease burden so the main treatment can work better. For investors, it matters because success or failure can change a therapy’s market potential, affect clinical trial outcomes and approval chances, and influence downstream use of a drug across more patients, similar to how a primer improves paint adhesion before a major renovation.

er+ /her2- medical

"node-positive ER+ /HER2- early breast cancer: Independent validation"

ER+ / HER2- describes a cancer subtype whose tumor cells show the presence of estrogen receptors (ER+) but do not overexpress the HER2 protein (HER2-), a common way doctors classify breast tumors. This classification matters to investors because it determines which treatments are likely to work, influences a drug’s target market and pricing, and shapes clinical trial design and expected sales—like knowing which lock a key will fit when assessing demand for different therapies.

colonoscopy medical

"Adenoma Detection Following Screening Colonoscopy and Stool-Based"

A colonoscopy is a medical procedure that uses a flexible tube with a tiny camera to inspect the large intestine for polyps, cancer, and other issues; doctors can remove growths or take samples during the same visit, like fixing a problem while doing a home inspection. Investors care because the number of colonoscopies affects revenue for hospitals, device makers, labs and insurers, and changes in screening guidelines, technology or reimbursement can shift demand and profits.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

• Data highlight how screening and diagnostics enable earlier detection, more precise treatment decisions, and improved patient outcomes from risk to remission
• New MRD data from the PARTNER study demonstrate enhanced sensitivity in early triple-negative breast cancer
• Early MCED prospective data show low anxiety and minimal psychological burden in real-world use

ABBOTT PARK, Ill., May 26, 2026 /PRNewswire/ -- Abbott (NYSE: ABT) will present 11 abstracts featuring new evidence across the cancer care continuum at the American Society of Clinical Oncology (ASCO) Annual Meeting, taking place May 29 – June 2, 2026, in Chicago. The presentations showcase the breadth of Abbott's integrated cancer diagnostics portfolio and demonstrate how its tests support critical decision points—from identifying risk and detecting disease earlier to guiding treatment and monitoring for recurrence.

The data indicate a shift in oncology toward more precise detection, improved personalized care, and clearer treatment decisions without adding patient burden or stress.

"Cancer care is at an inflection point, and diagnostics are playing an increasingly central role in how the disease is detected, treated and managed," said Jake Orville, senior vice president, Abbott's cancer diagnostics business. "By combining tools used for screening, early detection, treatment guidance and recurrence monitoring, we're helping clinicians make more informed decisions at every stage of cancer care, from risk through remission."

Abstract Presentations at ASCO 2026

The Cancerguard^® Multi-Cancer Early Detection (MCED) Test

Session times: Monday, June 1, 2026, from 1:30 p.m. to 4:30 p.m. CT

• Beyond Detection: Five-Year Screening Behaviors and Patient-Reported Perceptions in DETECT-A Participants
• Cancer Recognition and Assessment through Non-invasive Evaluation (CRANE) – a prospective clinical validation study of a multi-biomarker class multi-cancer early detection (MCED) test in Japan
• Prospective Evaluation of the Psychological Impact of Multicancer Early Detection (MCED) Blood Testing: A Smartphone-Based Patient Reported Outcomes Study

The Oncodetect^® Molecular Residual Disease (MRD) Test

Session times: Monday, June 1, 2026, from 1:30 p.m. to 4:30 p.m. CT 

• Evaluation of whole-exome & whole-genome sequencing tumor-informed circulating tumor DNA MRD assays in patients with early triple-negative breast cancer (TNBC) receiving neoadjuvant chemotherapy (NAC) with or without olaparib: A prospective sub-study of the PARTNER trial
• Characteristics of cancer patients undergoing molecular residual disease testing with a tumor-informed assay

The Oncotype DX Breast Recurrence Score^® Test

Session times: Monday, June 1, 2026, from 1:30 p.m. to 4:30 p.m. CT

• AI-driven risk stratification for distant recurrence in node-positive ER+ /HER2- early breast cancer: Independent validation in the NSABP B-28 trial
• Neoadjuvant 21-gene Breast Recurrence Score redirects surgical and systemic treatment pathways in early breast cancer: a multicenter prospective study
• Systemic cytokine dynamics during neoadjuvant chemotherapy versus endocrine therapy and CDK4/6 inhibition in high-risk luminal breast cancer: results from the GEICAM/2019-01-CARABELA trial

Session time: Monday, June 1, 2026, at 10:51 a.m. 

• Role of neoadjuvant versus adjuvant chemotherapy, dose density, and treatment schedule in biologically high-risk HR+/HER2- breast cancer: a pooled analysis of the WSG ADAPT-HR+/HER2- and PlanB trials

Pipeline Innovation

Session time: Monday, June 1, 2026, from 9:00 a.m. to 12:00 p.m. CT

• Development of an Endometrial Cancer Test from a Vaginal Swab

The Cologuard^® Test

Session time: Online Only

• Adenoma Detection Following Screening Colonoscopy and Stool-Based Colorectal Cancer Screening Tests with Follow-Up Colonoscopy: A Systematic and Network Meta-Analysis

About Abbott
Abbott is a global healthcare leader that helps people live more fully at all stages of life. Our portfolio of life-changing technologies spans the spectrum of healthcare, with leading businesses and products in diagnostics, medical devices, nutritionals and branded generic medicines. Our 122,000 colleagues serve people in more than 160 countries. Connect with us at abbott.com and on LinkedIn,  Facebook,  Instagram,  X and YouTube.

View original content:https://www.prnewswire.com/news-releases/abbott-showcases-expanding-evidence-across-its-cancer-diagnostics-portfolio-at-asco-2026-302779559.html

SOURCE Abbott

FAQ

What is Abbott (NYSE:ABT) presenting at ASCO 2026 in cancer diagnostics?

Abbott is presenting 11 abstracts at ASCO 2026 covering its integrated cancer diagnostics portfolio. According to Abbott, these span screening, early detection, treatment guidance and recurrence monitoring across breast, colorectal and multi-cancer settings, highlighting tools from risk assessment through remission management.

What new data on the Cancerguard multi-cancer early detection test will Abbott share at ASCO 2026?

Abbott will present multiple Cancerguard MCED abstracts at ASCO 2026. According to Abbott, these include five-year screening behaviors and patient perceptions from DETECT-A, a CRANE validation study in Japan, and prospective evaluation of psychological impact using smartphone-based patient-reported outcomes in real-world blood testing.

What does Abbott’s PARTNER trial MRD data show for early triple-negative breast cancer at ASCO 2026?

Abbott reports new molecular residual disease data from the PARTNER study in early triple-negative breast cancer. According to Abbott, evaluation of tumor-informed circulating tumor DNA MRD assays using whole-exome and whole-genome sequencing assesses patients receiving neoadjuvant chemotherapy with or without olaparib, focusing on test sensitivity.

How is Abbott using the Oncotype DX Breast Recurrence Score test in its ASCO 2026 presentations?

Abbott will feature several abstracts on the Oncotype DX Breast Recurrence Score test. According to Abbott, topics include AI-driven risk stratification for distant recurrence in node-positive ER+/HER2- early breast cancer and how neoadjuvant 21-gene scores redirect surgical and systemic treatment pathways in multicenter studies.

What pipeline innovation in endometrial cancer testing is Abbott highlighting at ASCO 2026?

Abbott is presenting pipeline innovation data on an endometrial cancer test developed from a vaginal swab. According to Abbott, this abstract appears in a pipeline session on June 1, 2026, from 9:00 a.m. to 12:00 p.m. CT, reflecting new sample collection approaches.

What colorectal cancer screening research involving the Cologuard test is Abbott presenting at ASCO 2026?

Abbott will showcase an online-only abstract relating to the Cologuard colorectal cancer screening test. According to Abbott, the systematic and network meta-analysis evaluates adenoma detection following screening colonoscopy and stool-based colorectal cancer screening tests followed by colonoscopy, comparing detection outcomes across modalities.

When are Abbott’s major ASCO 2026 sessions scheduled for its cancer diagnostics portfolio?

Abbott’s key ASCO 2026 sessions occur mainly on Monday, June 1, 2026. According to Abbott, Cancerguard, Oncodetect MRD and Oncotype DX abstracts run 1:30–4:30 p.m. CT, with a pipeline innovation session 9:00 a.m.–12:00 p.m. CT and an additional talk at 10:51 a.m.